Non-alcoholic Steatohepatitis Biomarkers Market (2025 - 2030) Size, Share & Trends Analysis Report By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), By End Use (Pharma & CRO Industry, Hospitals), By Region, And Segment Forecasts

Non-alcoholic Steatohepatitis Biomarkers Market Summary

Growing awareness and advancements in diagnostics are the major driving factors encouraging the demand for early detection and better management of the disease. Novel diagnostic tests offer more accurate, noninvasive ways to assess liver damage, thus boosting the adoption of biomarkers for personalized treatment plans. With NASH cases on the rise globally, healthcare providers are increasingly relying on these biomarkers, propelling the market growth and encouraging innovation in diagnostic solutions.

NASH has been one of the most difficult diseases for the diagnostics industry to manage, owing to non-specific or silent symptoms, which resulted in patients being unaware until the late stages of the disease. This hinders the diagnosis of the disease, limiting the overall growth of the market. Studies are being conducted to develop novel functional tests. These tests measure changes in liver function before the condition reaches the stage of fibrosis. In addition, breath tests are being considered for the detection of molecules and compounds associated with NASH. These tests are projected to provide robust information and compete with biomarker tests.

Type Insights

The serum biomarkers segment dominated the non-alcoholic steatohepatitis biomarkers industry with the largest revenue share of 31.2% in 2024 due to their noninvasive nature and ability to provide critical insights into disease progression. These biomarkers offer convenience and efficiency, enabling early detection and monitoring of NASH without the need for invasive liver biopsies. Furthermore, serum biomarkers are cost-effective and suitable for routine clinical use, driving their adoption among healthcare professionals. Their effectiveness in assessing liver inflammation, fibrosis, and overall metabolic dysfunction further solidifies their dominance in the market.

The hepatic fibrosis biomarkers segment is anticipated to grow at a significant CAGR of 23.7% from 2025 to 2030, attributed totheir pivotal role in assessing liver damage and fibrosis progression. These biomarkers enable early identification of advanced fibrosis stages, which is crucial for determining disease severity and treatment options. The growing demand for noninvasive diagnostic tools further boosts their adoption, as they help avoid costly and uncomfortable liver biopsies. Moreover, advancements in biomarker technology and their potential for personalized treatment plans are anticipated to drive significant growth in this segment.

End Use Insights

The pharma & CRO industry segment held the largest revenue share in 2024, owing to their integral role in drug development and clinical trials. Pharmaceutical companies focus on developing therapies for NASH, creating a strong demand for reliable biomarkers to monitor disease progression and treatment responses. CROs contribute by providing specialized services for clinical trials, helping pharmaceutical companies efficiently validate biomarkers. This collaboration accelerates the identification of effective treatments, boosting the market share of the pharma and CRO industries in the NASH biomarker space.

The diagnostic labs segment is expected to witness significant CAGR during the forecast period, propelled by the increasing demand for early detection and personalized treatment of NASH. These labs play a vital role in identifying biomarkers that help diagnose the disease at its onset, enabling more effective management. The rising global prevalence of NASH, coupled with advancements in biomarker testing technologies, drives the demand for diagnostic services. Growing awareness and a shift toward noninvasive diagnostic methods further enhance the segment's potential in the non-alcoholic steatohepatitis biomarkers industry.

Regional Insights

North America non-alcoholic steatohepatitis biomarkers market dominated the global market with the largest revenue share of 53.9% in 2024. This share is attributable to the increasing diagnosis rate of NASH. Enhanced awareness and better diagnostic technologies aid accurate detection of the disease. In addition, the early launch of novel products and biomarkers in the market fosters innovation and improves treatment outcomes. This combination of higher diagnosis rates and the introduction of advanced tools is accelerating the growth of the non-alcoholic steatohepatitis biomarkers industry in North America, driving demand for more effective and tailored diagnostic solutions.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Trends

TheU.S. non-alcoholic steatohepatitis biomarkers market held the largest share in the regional market in 2024.The growing prevalence of NASH in the U.S., driven by rising obesity and diabetes rates, is significantly boosting the demand for NASH biomarkers. Increased awareness about disease and the need for early detection are compelling healthcare providers to adopt advanced diagnostic methods. Noninvasive testing technologies, including blood biomarkers and imaging techniques, are gaining popularity due to their accuracy, safety, and cost-effectiveness, reducing the need for invasive liver biopsies. These innovations fuel market growth and encourage the development of more precise and accessible NASH diagnostic tools.

Europe Non-alcoholic Steatohepatitis Biomarkers Market Trends

Europe non-alcoholic steatohepatitis biomarkers market is anticipated to experience significant expansion over the forecast period. The growing emphasis on early detection and diagnosis of NASH significantly boosts the demand for biomarkers in Europe. Early intervention can improve treatment outcomes, reducing the risk of severe liver damage. Furthermore, the shift toward personalized treatment plans tailored to individual patients' needs is encouraging the development of more precise biomarkers. This dual focus on early detection and customized therapies is expected to drive the growth of the non-alcoholic steatohepatitis biomarkers industry in Europe as healthcare providers seek more accurate and efficient diagnostic tools.

Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Trends

Asia Pacific non-alcoholic steatohepatitis biomarkers market is set to be the fastest-growing region with a CAGR of 24.9% from 2025 to 2030 due to expanding healthcare infrastructure and increasing R&D investments by biotech companies. Enhancing regional healthcare facilities enables better diagnostic capabilities and access to advanced biomarkers. Biotech companies are significantly investing in research and development to discover more accurate, noninvasive biomarkers, addressing the rising demand for early-stage NASH detection. This collaborative push toward innovation is expected to accelerate market growth by improving diagnostic accuracy, treatment outcomes, and overall disease management in the region.

India Non-alcoholic Steatohepatitis Biomarkers Market Trends

India non-alcoholic steatohepatitis biomarkers market is projected to grow at the fastest CAGR in the regional market during the forecast period, fueled bythe increasing demand for noninvasive diagnostic methods in the country. Patients and healthcare providers prefer noninvasive approaches to avoid the discomfort and risks associated with liver biopsies. Moreover, advancements in biomarker discovery technologies are improving the accuracy and efficiency of diagnosing NASH, leading to better early detection and monitoring of the disease. These factors are expected to significantly expand the market, offering innovative solutions to meet the growing healthcare needs in India.

Key Non-alcoholic Steatohepatitis Biomarkers Company Insights

Some of the key companies in the non-alcoholic steatohepatitis biomarkers industry include Siemens Healthineers AG; AstraZeneca; Labcorp; Pfizer Inc.; and Bristol-Myers Squibb Company.

• Pfizer Inc. provides innovative healthcare solutions, including vaccines, biologics, and prescription medications. Its products target a wide range of conditions, such as cancer, cardiovascular diseases, infectious diseases, and immunological disorders, enhancing global health outcomes.

• Bristol-Myers Squibb Company offers innovative medicines, focusing on oncology, immunology, cardiology, and fibrosis. Its portfolio includes biologics, small molecules, and cell therapies, aimed at addressing serious diseases and improving patient outcomes globally.

Recent Developments

• In July 2024, SomaLogic, a leading protein biomarker discovery and clinical diagnostics company, introduced new biomarkers and provided mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) for diagnosis of Non-alcoholic Steatohepatitis (NASH).

• In February 2024, Gilead Sciences agreed to acquire CymaBay Therapeutics for USD 4.3 billion to expand its liver disease treatment portfolio. Gilead included also Seladelpar, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) to their portfolio.

Non-alcoholic Steatohepatitis Biomarkers Market Report Scope

Global Non-alcoholic Steatohepatitis Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global non-alcoholic steatohepatitis biomarkers market report on the basis of type, end use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Serum Biomarkers

  • Hepatic Fibrosis Biomarkers

  • Apoptosis Biomarkers

  • Oxidative Stress Biomarkers

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharma & CRO Industry

  • Hospitals

  • Diagnostic Labs

  • Academic Research Institutes

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait